Carrier molecules for use in veterinary vaccines

Vaccine

Volumn 31, Issue 4, 2013, Pages 596-602

  Gerdts, Volker ^a   Mutwiri, George ^a   Richards, James ^b   Hurk, Sylvia van Drunen Littel van den ^a   Potter, Andrew A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Carrier; Conjugate; Microparticle; Nanoparticle; Veterinary vaccine; Virus like particle

Indexed keywords

ALGINIC ACID; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; DRUG CARRIER; GAMMA INTERFERON; GLYCOCONJUGATE; GLYCOCONJUGATE VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 6; LIPOSOME; NANOPARTICLE; PEPTIDE VACCINE; POLY[DI(SODIUM CARBOXYLATOETHYLPHENOXY] PHOSPHAZENE; POLY[DI(SODIUM CARBOXYLATOPHENOXY)] POLYPHOSPHAZENE; POLYGLACTIN; POLYMER; POLYSACCHARIDE VACCINE; STARCH; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ACTINOBACILLUS PLEUROPNEUMONIAE; ANTIGEN PRESENTING CELL; ATROPHIC RHINITIS; BACTERIAL LOAD; BORDETELLA BRONCHISEPTICA; BRONCHOPNEUMONIA; CD8+ T LYMPHOCYTE; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOGENICITY; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; NONHUMAN; PASTEURELLA MULTOCIDA INFECTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; VIRUS LIKE AGENT;

ANIMALS; GLYCOCONJUGATES; NANOPARTICLES; VACCINATION; VACCINES; VACCINES, CONJUGATE; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84871938743     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.067     Document Type: Review

References (84)

1. Heidelberger M., Dilapi M.M., Siegel M., Walter A.W. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol 1950, 65(November (5)):535-541.
2. Robbins J.B., Austrian R., Lee C.J., Rastogi S.C., Schiffman G., Henrichsen J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983, 148(December (6)):1136-1159.
3. Pon R., Jennings H. Carbohydrate-based antibacterial vaccines. Carbohydrate-Based Vaccines and Immunotherapies 2009, 117-166. John Wiley & Sons, Hoboken, NJ. Z. Guo, G.-J. Boons (Eds.).
4. Astronomo R.D., Burton D.R. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat Rev Drug Discov 2010, 9(April (4)):308-324.
5. Robbins J.B., Schneerson R., Anderson P., Smith D.H. The 1996 Albert Lasker Medical Research Awards. Prevention of systemic infections, especially meningitis, caused by Haemophilus influenzae type b. Impact on public health and implications for other polysaccharide-based vaccines. JAMA 1996, 276(October (14)):1181-1185.
6. Zou W., Jennings H. Preparation of glycoconjugate vaccines. Carbohydrate-Based Vaccines and Immunotherapies 2009, 55-88. John Wiley & Sons, Hoboken, NJ. Z. Guo, G.-J. Boons (Eds.).
7. Byrd W., Kadis S. Preparation, characterization, and immunogenicity of conjugate vaccines directed against Actinobacillus pleuropneumoniae virulence determinants. Infect Immun 1992, 60(August (8)):3042-3051.
8. St Michael F., Cairns C., Filion A.L., Neelamegan D., Lacelle S., Cox A.D. Investigating the candidacy of lipopolysaccharide-based glycoconjugates as vaccines to combat Mannheimia haemolytica. Glycoconj J 2011, 28(August (6)):397-410.
9. Kubler-Kielb J., Vinogradov E., Ben-Menachem G., Pozsgay V., Robbins J.B., Schneerson R. Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates. Vaccine 2008, 26(July (29-30)):3587-3593.
10. Nothaft H., Szymanski C.M. Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 2010, 8(November (11)):765-778.
11. Ihssen J., Kowarik M., Dilettoso S., Tanner C., Wacker M., Thony-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010, 9:61.
12. Iwashkiw J.A., Fentabil M.A., Faridmoayer A., Mills D.C., Peppler M., Czibener C., et al. Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis. Microb Cell Fact 2012, 11:13.
13. Nyame A.K., Kawar Z.S., Cummings R.D. Antigenic glycans in parasitic infections: implications for vaccines and diagnostics. Arch Biochem Biophys 2004, 426(June (2)):182-200.
14. van Stijn C.M., van den Broek M., Vervelde L., Alvarez R.A., Cummings R.D., Tefsen B., et al. Vaccination-induced IgG response to Galalpha1-3GalNAc glycan epitopes in lambs protected against Haemonchus contortus challenge infection. Int J Parasitol 2010, 40(February (2)):215-222.
15. Seeberger P.H., Werz D.B. Synthesis and medical applications of oligosaccharides. Nature 2007, 446(April (7139)):1046-1051.
16. Boler DD. Effects of gonadotropin releasing factor immunological (Improvest®) on carcass characteristics, pork quality, and further processing characteristics of finishing male pigs [Ph.D.]. Urbana: University of Illinois at Urbana-Champaign; 2011.
17. Dunshea F.R., Colantoni C., Howard K., McCauley I., Jackson P., Long K.A., et al. Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance. J Anim Sci 2001, 79(October (10)):2524-2535.
18. Sad S., Talwar G.P., Raghupathy R. Influence of the genetic background and carrier protein on the antibody response to GnRH. J Reprod Immunol 1991, 19(February (2)):197-207.
19. Coote J.G. Structural and functional relationships among the RTX toxin determinants of gram-negative bacteria. FEMS Microbiol Rev 1992, 8(February (2)):137-161.
20. Lally E.T., Hill R.B., Kieba I.R., Korostoff J. The interaction between RTX toxins and target cells. Trends Microbiol 1999, 7(September (9)):356-361.
21. Potter AA, Manns JG, inventors; University of Saskatchewan, assignee. GnRH leukotoxin chimeras. US Patent 5,723,129. 1998 March 3, 1998.
22. Potter AA, Manns JG, inventors; University of Saskatchewan, assignee. GnRH-leukotoxin chimeras. US Patent 5,837,268. 1998 November 17, 1998.
23. Potter AA, Manns JG, inventors; University of Saskatchewan, assignee. Polynucleotides Encoding LKT 111. US Patent 6,521,746 B1. 2003 February 18, 2003.
24. Potter AA, Redmond MJ, Hughs HPA, inventors; University of Saskatchewan, assignee. Enhanced immunogenicity using leukotoxin chimeras. US Patent 5,422,110. 1995 June 6, 1995.
25. Potter AA, Redmond MJ, Hughs HPA, inventors; University of Saskatchewan, assignee. Enhanced immunogenicity using leukotoxin chimeras. US Patent 5,708,155. 1998 January 13, 1998.
26. Harland R.J., Potter A.A., van Drunen-Littel-van den Hurk S., Van Donkersgoed J., Parker M.D., Zamb T.J., et al. The effect of subunit or modified live bovine herpesvirus-1 vaccines on the efficacy of a recombinant Pasteurella haemolytica vaccine for the prevention of respiratory disease in feedlot calves. Can Vet J 1992, 33:734-741.
27. Potter A.A., Harland R.J., Hughes H. Recombinant vaccines for Pastuerella haemolytica. Pasteurellosis in Production Animals 1993, 170-174. ICAR Press, Brisbane. Patten Bea (Ed.).
28. Rossi-Campos A., Anderson C., Gerlach G.F., Klashinsky S., Potter A.A., Willson P.J. Immunization of pigs against Actinobacillus pleuropneumoniae with two recombinant protein preparations. Vaccine 1992, 10(8):512-518.
29. Potter AA, Redmond MJ, Hughs HPA, inventors; University of Saskatchewan, assignee. Enhanced immunogenicity using leukotoxin chimeras. US Patent 6,797,272. 2004 September 28, 2004.
30. Hedlin P.D., Taschuk R., Potter A., Griebel P., Napper S. Detection and control of prion diseases in food animals. Vet Sci 2012, 2012:1-24.
31. Rebelatto M.C., Guimond P., Bowersock T.L., HogenEsch H. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 2001, 83(November (1-2)):93-105.
32. Bowersock T.L., HogenEsch H., Torregrosa S., Borie D., Wang B., Park H., et al. Induction of pulmonary immunity in cattle by oral administration of ovalbumin in alginate microspheres. Immunol Lett 1998, 60(January (1)):37-43.
33. Arenas-Gamboa A.M., Ficht T.A., Davis D.S., Elzer P.H., Kahl-McDonagh M., Wong-Gonzalez A., et al. Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J Wildl Dis 2009, 45(October (4)):1021-1029.
34. Arenas-Gamboa A.M., Ficht T.A., Davis D.S., Elzer P.H., Wong-Gonzalez A., Rice-Ficht A.C. Enhanced immune response of red deer (Cervus elaphus) to live rb51 vaccine strain using composite microspheres. J Wildl Dis 2009, 45(January (1)):165-173.
35. Felder C.B., Vorlaender N., Gander B., Merkle H.P., Bertschinger H.U. Microencapsulated enterotoxigenic Escherichia coli and detached fimbriae for peroral vaccination of pigs. Vaccine 2000, 19(November (7-8)):706-715.
36. O'Brien C.N., Guidry A.J., Fattom A., Shepherd S., Douglass L.W., Westhoff D.C. Production of antibodies to Staphylococcus aureus serotypes 5, 8, and 336 using poly(dl-lactide-co-glycolide) microspheres. J Dairy Sci 2000, 83(August (8)):1758-1766.
37. Stanley A.C., Buxton D., Innes E.A., Huntley J.F. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004, 22(September (29-30)):3929-3941.
38. Niborski V., Li Y., Brennan F., Lane M., Torche A.M., Remond M., et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 2006, 24(November (49-50)):7204-7213.
39. Brandhonneur N., Chevanne F., Vie V., Frisch B., Primault R., Le Potier M.F., et al. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009, 36(March (4-5)):474-485.
40. Andrianov A.K., DeCollibus D.P., Gillis H.A., Kha H.H., Marin A., Prausnitz M.R., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci USA 2009, 106(November (45)):18936-18941.
41. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2010, 29(December (38)):6540-6548.
42. Garlapati S., Eng N.F., Wilson H.L., Buchanan R., Mutwiri G.K., Babiuk L.A., et al. PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice. Vaccine 2011, 28(September (52)):8306-8314.
43. Kovacs-Nolan J., Mapletoft J.W., Latimer L., Babiuk L.A., Hurk S.D. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 2009, 27(March (14)):2048-2054.
44. Harpin S., Hurley D.J., Mbikay M., Talbot B., Elazhary Y. Vaccination of cattle with a DNA plasmid encoding the bovine viral diarrhoea virus major glycoprotein E2. J Gen Virol 1999, 80(Pt 12):3137-3144.
45. Kakuda T., Sugimoto C., Onuma M. Epitope-Mapping of antigen-specific T lymphocyte in cattle immunized with recombinant major piroplasm surface protein of Theileria sergenti. J Vet Med Sci/Japanese Soc Vet Sci 2001, 63(August (8)):895-901.
46. Doroud D., Rafati S. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. Expert Rev Vaccines 2012, 11(January (1)):69-86.
47. Nembrini C., Stano A., Dane K.Y., Ballester M., van der Vlies A.J., Marsland B.J., et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci USA 2011, 108(November (44)):E989-E997.
48. Ballester M., Nembrini C., Dhar N., de Titta A., de Piano C., Pasquier M., et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 2011, 29(September (40)):6959-6966.
49. Mutwiri G. TLR9 agonists: immune mechanisms and therapeutic potential in domestic animals. Vet immunol immunopathol 2012, 148(July (1-2)):85-89.
50. Demento S.L., Bonafe N., Cui W., Kaech S.M., Caplan M.J., Fikrig E., et al. TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 2010, 185(September (5)):2989-2997.
51. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(February (2)):187-192.
52. Tacken P.J., Zeelenberg I.S., Cruz L.J., van Hout-Kuijer M.A., van de Glind G., Fokkink R.G., et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011, 118(December (26)):6836-6844.
53. Zhao K., Shi X., Zhao Y., Wei H., Sun Q., Huang T., et al. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 2011, 29(November (47)):8549-8556.
54. Zhao Z.Z., Zhang H.B., Chen Q., Su D., Xie Z., Wang Y.Y., et al. Promotion of immunity of mice to Pasteurella multocida and hog cholera vaccine by pig interleukin-6 gene and CpG motifs. Comp Immunol Microbiol Infect Dis 2009, 32(May (3)):191-205.
55. Yang Y., Chen J., Li H., Wang Y., Xie Z., Wu M., et al. Porcine interleukin-2 gene encapsulated in chitosan nanoparticles enhances immune response of mice to piglet paratyphoid vaccine. Comp Immunol Microbiol Infect Dis 2007, 30(January (1)):19-32.
56. Joyappa D.H., Kumar C.A., Banumathi N., Reddy G.R., Suryanarayana V.V. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Vet Microbiol 2009, 139(October (1-2)):58-66.
57. Wang G., Pan L., Zhang Y., Wang Y., Zhang Z., Lu J., et al. Intranasal delivery of cationic PLGA nano/microparticles-loaded FMDV DNA vaccine encoding IL-6 elicited protective immunity against FMDV challenge. PLoS One 2011, 6(11):e27605.
58. Vandamme K., Melkebeek V., Cox E., Remon J.P., Vervaet C. Adjuvant effect of Gantrez(R)AN nanoparticles during oral vaccination of piglets against F4+enterotoxigenic E. coli. Vet Immunol Immunopathol 2011, 139(February (2-4)):148-155.
59. Zhang W., Yin Z., Liu N., Yang T., Wang J., Bu Z., et al. DNA-chitosan nanoparticles improve DNA vaccine-elicited immunity against Newcastle disease virus through shuttling chicken interleukin-2 gene. J Microencapsul 2010, 27(8):693-702.
60. Huang J., Yin Y., Pan Z., Zhang G., Zhu A., Liu X., et al. Intranasal immunization with chitosan/pCAGGS-flaA nanoparticles Inhibits Campylobacter jejuni in a white Leghorn model. J Biomed Biotechnol 2010, 2010:8. [Article ID 589476].
61. Fredriksen B.N., Saevareid K., McAuley L., Lane M.E., Bogwald J., Dalmo R.A. Early immune responses in Atlantic salmon (Salmo salar L.) after immunization with PLGA nanoparticles loaded with a model antigen and beta-glucan. Vaccine 2011, 29(October (46)):8338-8349.
62. Fredriksen B.N., Grip J. PLGA/PLA micro- and nanoparticle formulations serve as antigen depots and induce elevated humoral responses after immunization of Atlantic salmon (Salmo salar L.). Vaccine 2012, 30(January (3)):656-667.
63. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biol Chem 2008, 389(May (5)):521-536.
64. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J Control Release 2002, 79(February (1-3)):29-40.
65. Bruss V., Gerhardt E., Vieluf K., Wunderlich G. Functions of the large hepatitis B virus surface protein in viral particle morphogenesis. Intervirology 1996, 39(1-2):23-31.
66. Chege G.K., Shephard E.G., Meyers A., van Harmelen J., Williamson C., Lynch A., et al. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 2008, 89(September (Pt 9)):2214-2227.
67. Chiu H.C., Wang F.D., Yao S.Y., Wang C.T. Effects of gag mutations on human immunodeficiency virus type 1 particle assembly, processing, and cyclophilin A incorporation. J Med Virol 2002, 68(October (2)):156-163.
68. Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 2009, 4(4):e4991.
69. Ettayebi K., Hardy M.E. Recombinant norovirus-specific scFv inhibit virus-like particle binding to cellular ligands. Virol J 2008, 5:21.
70. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 3(1):e1501.
71. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26(October (42)):5393-5399.
72. Redmond M.J., Ohmann H.B., Hughes H.P., Sabara M., Frenchick P.J., Poku S.K., et al. Rotavirus particles function as immunological carriers for the delivery of peptides from infectious agents and endogenous proteins. Mol Immunol 1991, 28(March (3)):269-278.
73. Redmond M.J., Ijaz M.K., Parker M.D., Sabara M.I., Dent D., Gibbons E., et al. Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential. Vaccine 1993, 11(2):273-281.
74. Blanchet M., Sureau C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol 2006, 80(December (24)):11935-11945.
75. Pumpens P., Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001, 44(2-3):98-114.
76. Jegerlehner A., Tissot A., Lechner F., Sebbel P., Erdmann I., Kundig T., et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20(August (25-26)):3104-3112.
77. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Wetzel K., Maier C., Birkett A.J., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004, 72(November (11)):6519-6527.
78. Bachmann M.F., Zinkernagel R.M. The influence of virus structure on antibody responses and virus serotype formation. Immunol Today 1996, 17(December (12)):553-558.
79. Thyagarajan R., Arunkumar N., Song W. Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains. J Immunol 2003, 170(June (12)):6099-6106.
80. Matsushita M., Fujita T. Ficolins and the lectin complement pathway. Immunol Rev 2001, 180(April):78-85.
81. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001, 166(May (9)):5346-5355.
82. McCluskie M.J., Krieg A.M. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol 2006, 311:155-178.
83. Jegerlehner A., Maurer P., Bessa J., Hinton H.J., Kopf M., Bachmann M.F. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007, 178(February (4)):2415-2420.
84. Estes M.K., Ball J.M., Crawford S.E., O'Neal C., Opekun A.A., Graham D.Y., et al. Virus-like particle vaccines for mucosal immunization. Adv Exp Med Biol 1997, 412:387-395.